Vantage logo

Amylyx’s fortunes shift again

FDA approval of the company’s ALS project seems assured, but pledges of withdrawal on phase 3 failure come with caveats.

Vantage logo

Amylyx faces an uphill battle

Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?